UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CLINICAL RESEARCH

Care Fertility

C

Care Fertility

Clinical ResearchNottingham, United Kingdom
Visit Website

About Care Fertility

Care Fertility is one of the United Kingdom's largest independent providers of fertility treatment, operating a network of specialist clinics across England and Scotland. Founded in 1997, the group has grown into a leading name in reproductive medicine, offering the full spectrum of assisted conception services to patients and clinical partners alike.

The clinic network covers treatments including IVF, ICSI, egg freezing, donor egg and donor sperm programmes, preimplantation genetic testing (PGT), and fertility preservation for patients facing medical circumstances such as cancer treatment. Care Fertility has invested substantially in its embryology laboratories and scientific infrastructure, and the group has been associated with research into embryo selection and time-lapse imaging technology.

Care Fertility clinics hold licences from the Human Fertilisation and Embryology Authority (HFEA), the UK's statutory regulator for fertility treatment and embryo research, and the group publishes success rate data in line with HFEA reporting requirements. This transparency is central to how the network positions itself within the competitive UK fertility sector.

The group serves both self-funding patients and those accessing NHS-funded cycles through clinical commissioning arrangements. Its clinics are located in cities including Nottingham, Manchester, Sheffield, Leeds, Birmingham, and London, giving the network broad geographic coverage across the country.

Further information is available at carefertility.com.

Similar Companies

More in Clinical Research

F

Flatiron Health

Founded in 2012 and acquired by Roche in 2018, Flatiron Health has become the leading oncology-specific technology and real-world evidence company in the United States, connecting cancer care and research through a purpose-built data infrastructure. Its work centres on the premise that the information generated during routine cancer treatment holds untapped research value when structured and analysed correctly. The company operates the OncoEMR electronic health record platform, used by community oncology practices across the country, alongside the broader oncology network that aggregates de-identified real-world data from millions of cancer patients. This dataset supports regulatory submissions, label expansions, health technology assessments, and clinical trial optimisation for pharmaceutical and biotechnology companies worldwide. Flatiron's research services division works directly with life sciences sponsors and regulators, including the US Food and Drug Administration, to explore how real-world evidence can supplement or accelerate traditional clinical development pathways. The company is headquartered in New York City and operates as a subsidiary of the Roche Group, giving it access to global oncology expertise while maintaining a focused mandate on cancer data science. Its therapy coverage spans solid tumours and haematological malignancies, with data assets covering breast cancer, lung cancer, colorectal cancer, leukaemia, lymphoma, and many additional indications. Researchers and commercial teams use Flatiron's curated datasets to understand treatment patterns, patient outcomes, and population-level trends in ways that prospective trials alone cannot capture. Further information is available at flatiron.com.

View profile
A

Affinity

Combining mobile nursing, teletrials and a dedicated oncology unit, Affinity Clinical Research Services brings clinical research capability directly to patients across Perth and the wider Australian continent. Operating from Doubleview in Western Australia and from a research facility within Hollywood Private Hospital Medical Centre, the organisation serves pharmaceutical sponsors, biotechnology companies and independent investigators seeking a flexible, patient-centred site partner. Affinity's service model covers the full research lifecycle, from protocol development and site feasibility through participant recruitment, data collection and publication support. The company's direct-to-patient and mobile trial services reduce the burden on participants who would otherwise be unable to access a fixed trial site, extending sponsor reach into regional and rural populations. This approach aligns with ICH-GCP guidelines and is adapted to the specific needs of each patient group and study design. The dedicated oncology division, Affinity Oncology, was established in 2016 and draws on clinical staff with more than a decade of experience in cancer trials. On-site resources include PET/CT imaging, a compounding pharmacy and a chemotherapy infusion suite, allowing complex oncology studies to run without reliance on third-party facilities. Beyond oncology, Affinity supports studies across a broad range of therapeutic areas and can assist private investigators running sponsor-initiated or investigator-initiated research. Further information is available at affinityresearch.com.au.

View profile
I

IVIRMA Global

The world's largest network of assisted reproduction clinics, IVIRMA Global was formed in 2017 when two established fertility leaders, IVI (founded 1990 in Valencia, Spain) and RMA (founded 1999 in the United States), merged to create a single, vertically integrated group spanning Europe, North America and Latin America. Headquartered in Valencia, the group has since grown to more than 200 clinical offices across 15 countries, treating patients who travel from more than 180 countries each year. Clinical Services Across the Reproductive Medicine Spectrum IVIRMA Global's clinical portfolio covers the full range of reproductive medicine, including in vitro fertilisation (IVF), intrauterine insemination, egg freezing and fertility preservation, third-party reproduction (donor eggs, donor sperm and gestational carriers), reproductive surgery (laparoscopy, hysteroscopy and myomectomy), and pre-implantation genetic testing. Services are structured to serve heterosexual couples, same-sex couples and single individuals. The group performs more than 200,000 assisted reproduction treatments annually, with approximately 100 babies born every day as a direct result of its programmes. Research, Science and the IVIRMA Innovation Network Scientific output is central to the group's identity. IVIRMA Innovation, its dedicated research arm, operates a network of fertility research centres and supports clinical trials, making the group one of the most cited organisations in peer-reviewed reproductive medicine literature. The group employs more than 6,000 people globally, including over 450 physicians and embryologists and more than 500 scientists and researchers. Patient-facing technology includes the Artemis Patient Portal, which centralises treatment management and communication. Financial access programmes, including a CareShare IVF refund programme, reflect a broader commitment to widening access to treatment. In 2025, IVIRMA Global continued its international expansion, acquiring ART Fertility Clinics in the United Arab Emirates and Saudi Arabia, extending its footprint into the Gulf region. Executive Chairman Dr Antonio Pellicer, one of the original founders of IVI, remains the public face of the group's scientific leadership. Further information is available at ivirma.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy